Stephen Harbin

Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA.

Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA.

Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA.

Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation.

Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA.

Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX.

MTrap, Inc. engages in the development of novel therapeutic devices that interfere with the intense dialogue and crosstalk between the primary tumor and the microenvironment and represent a new disruptive approach to cancer treatment. The company was founded by Maybelle L. Jordan and is headquartered in Huntington, NY.

Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA.

Civetta Therapeutics LLC develops therapeutics for cancers and other diseases. The company was founded by William Sellers and Eric Fischer and is headquartered in Cambridge, MA.

AlivaMab Discovery Services LLC is a private company that specializes in generating and screening large panels of antibodies to achieve their partners' design goals. AlivaMab Discovery Services is based in San Diego, CA. The company focuses on delivering antibodies that are characterized for function, kinetics, and developability, and engineering for advanced modalities, including multispecifics and cars. The company has experience in antibody drug discovery and development from many of the world's top pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, and Roche/Genentech. The company was founded by John Lippincott, and the CEO is Larry L. Green.

Pairwise Plants LLC operates as a agriculture company. The company was founded by Feng Zhang, David Liu and J. Keith Joung and is headquartered in Durham, NC.

Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation.

Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts.

Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA.

MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts.

Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer.

Charles River Associates (Asia Pacific) Ltd. provides economic, financial, and management consulting services. It is a subsidiary of CRA International, Inc. The company is headquartered in Brisbane, Australia.

Longwood Fund Management LLC (Longwood Fund Management) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Dipp and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts.

Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York.